Turkey's 1st Pediatric Patient to Receive
the SynCardia Total Artificial Heart
Celebrates 18th Birthday
Yusuf Enec Surpasses 8 Months of Support with the Freedom® Portable Driver
TUCSON, Ariz. – Aug. 1, 2013 – Turning 18 years old is an important milestone in any young man's life, but even more so for Yusuf Enec. This time last year, Yusuf wasn't sure he'd live to see it. However, thanks to the SynCardia temporary Total Artificial Heart, today he has the chance to celebrate.
"Before the operation, I was so weak that even turning newspaper pages was too difficult for me," said Yusuf. "But now, I can play soccer with my artificial heart."
Yusuf was diagnosed with end-stage heart failure affecting both sides of his heart (biventricular failure) in January 2012 at Dokuz Eylul University Hospital in Izmir, Turkey. His condition deteriorated quickly and he became dependent on inotropes, which are medicines that increase the force of the heart's contractions, and his kidneys began to fail.
On Oct. 17, 2012, Yusuf, then 17, became Turkey's first pediatric patient to receive the SynCardia Total Artificial Heart. The surgery was performed by Prof. Oztekin Oto in order to save Yusuf's life and bridge him to a heart transplant. His recovery went well and six weeks after the implant surgery, he was switched to the Freedom® portable driver, the world's first wearable power supply for the SynCardia Total Artificial Heart. He surpassed eight months of support with the Freedom driver on July 26.
"We have observed better quality of life and lower complication rates with the SynCardia Total Artificial Heart compared to other biventricular devices," said Prof. Oto. "This system is very good for pediatric patients suffering biventricular failure who have enough space for the Total Artificial Heart."
SynCardia recognizes and thanks Ufuk Yaranli and Natura Medikal Urunler Ltd., the Turkish distributor for the Total Artificial Heart, for their commitment and ongoing support of the six SynCardia Certified Centers in Turkey and the additional three Turkish hospitals currently undergoing SynCardia's four-phase certification process.
The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.
SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,350 implants of the SynCardia Total Artificial Heart accounts for over 400 patient years of life on the device. Since January 2011 more than 400 SynCardia Hearts have been implanted.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to leave the hospital to live at home and in their communities. The wearable Freedom driver has been used by 190 patients, accounting for over 110 years of support.